Testing effectiveness (Phase 2)Not Yet RecruitingNCT07715565
What this trial is testing
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
Who this might be right for
Renal Cell Carcinoma (Kidney Cancer)ImmunotherapyMolecular Targeted Therapy
West China Hospital 66